Endo Health Solutions Launches 7.5mg And 15mg Strengths Of Reformulated, Designed To Be Crush-Resistant, OPANA® ER

CHADDS FORD, Pa., Dec. 11, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that its subsidiary, Endo Pharmaceuticals Inc., has launched 7.5mg and 15mg strengths of its reformulated, designed to be crush-resistant, OPANA ^® ER (oxymorphone HCl) product.  Now commercially available, the 7.5mg and 15mg options complete the launch of all approved strengths of the reformulated version of OPANA ER with INTAC ^® technology.  The product is now available in seven dosage strengths: 5, 7.5, 10, 15, 20, 30 and 40mg.

"Considering that a substantial amount of abuse and misuse of opioid products is performed by manipulating the tablet through crushing and powdering, we are excited to offer patients and healthcare professionals a full line of strength options of the reformulated, designed to be crush-resistant, OPANA ^® ER," stated Julie McHugh, chief operating officer, Endo Health Solutions.  "Now healthcare professionals and patients have seven strength options for extended release oxymorphone (HCl) in a version designed to be crush-resistant.  We see this line completion as an important step forward for responsible pain management." 

With the launch of 7.5mg and 15mg OPANA ER designed to be crush-resistant, Endo filed a false advertising suit against Actavis calling for the company to cease and desist promoting its non-crush-resistant extended release oxymorphone HCl product as A-B rated, or bio-equivalent, to the reformulated OPANA ER.  The lawsuit was filed earlier today, Tuesday, December 11, 2012. 

As Endo reported in November, surveillance data collected by national independent sources through the third quarter of 2012 suggest that the introduction of reformulated OPANA ER designed to be crush-resistant in February reduced abuse rates of the product when compared to the non-crush-resistant version that Endo discontinued in May. Additionally, rates of abuse for the non-crush-resistant 7.5mg and 15mg oxymorphone HCl tablets marketed by Actavis appear to have increased more than 122 percent since Endo launched its reformulated OPANA ER version. 

1 2 3 Next › Last »